Table 1 Baseline characteristics in all patients and according to elevated blood pressure
Overall | Blood pressure non-elevation group (⊿SBP < 26 mmHg) | Blood pressure elevation group (⊿SBP ≥ 26 mmHg) | P value | |
|---|---|---|---|---|
n = 67 | n = 33 | n = 34 | ||
Age (years) | 71 (66–80) | 71 (66–80) | 72 (67–77) | 0.886 |
Male sex | 55 (82.1) | 27 (81.8) | 28 (82.4) | 0.955 |
BMI (kg/m2) | 23.1 (20.3–26.0) | 24.8 (21.0–26.8) | 22.1 (20.3–25.5) | 0.137 |
Smoking history | 46 (68.7) | 21 (63.6) | 25 (73.5) | 0.383 |
Habitual drinking history | 43 (64.2) | 20 (60.6) | 23 (67.7) | 0.548 |
Diabetes | 26 (38.8) | 10 (30.3) | 16 (47.1) | 0.159 |
Dyslipidemia | 26 (38.8) | 13 (39.4) | 13 (38.2) | 0.923 |
Hypertension | 40 (59.7) | 21 (63.6) | 19 (55.9) | 0.518 |
Antihypertensive medication | 38 (56.7) | 20 (60.6) | 18 (52.9) | 0.527 |
Baseline blood pressure | ||||
Systolic (mmHg) | 128 (116–136) | 131 (124–138) | 125 (114–132) | 0.048 |
Diastolic (mmHg) | 73 (62–80) | 75 (62–79) | 72 (64–81) | 0.939 |
Hepatocellular carcinoma | ||||
Stage | 0.192 | |||
II | 9 (13.4) | 2 (6.1) | 7 (20.6) | |
III | 28 (41.8) | 14 (42.4) | 14 (41.2) | |
IV | 30 (44.8) | 17 (51.5) | 13 (38.2) | |
ECOG-PS | 0.305 | |||
0 | 58 (86.6) | 30 (90.9) | 28 (82.4) | |
1 or higher | 9 (13.4) | 3 (9.1) | 6 (17.7) | |
history of treatment for hepatocellular carcinoma | ||||
surgical procedure | 21 (31.3) | 7 (21.2) | 14 (41.2) | 0.078 |
TACE | 50 (74.6) | 27 (81.8) | 23 (67.7) | 0.183 |
RFA | 14 (20.9) | 5 (15.2) | 9 (26.5) | 0.255 |
cancer pharmacotherapy | 16 (23.9) | 7 (21.2) | 9 (26.5) | 0.614 |
Etiology of chronic liver disease | 0.714 | |||
Hepatitis B | 15 (22.4) | 6 (18.2) | 9 (26.5) | |
Hepatitis C | 17 (25.4) | 9 (27.3) | 8 (23.5) | |
non B non C | 35 (52.2) | 18 (54.6) | 17 (50.0) | |
Initial dose | 0.767 | |||
4 mg | 12 (17.9) | 5 (15.2) | 7 (20.6) | |
8 mg | 33 (49.3) | 16 (48.5) | 17 (50.0) | |
12 mg | 22 (32.8) | 12 (36.4) | 10 (29.4) | |
Initial dose (mg/kg) | 0.149 (0.120–0.174) | 0.147 (0.118–0.176) | 0.155 (0.118–0.173) | 0.900 |
mALBI Grade 1 | 32 (47.8) | 15 (45.5) | 17 (50.0) | 0.710 |
Baseline laboratory values | ||||
White blood cell count (103/μL) | 5.3 (4.1–7.3) | 5.5 (4.1–7.4) | 5.0 (4.0–7.2) | 0.701 |
Hemoglobin (g/dL) | 13.0 (11.8–13.8) | 13.5 (11.8–13.9) | 12.9 (11.9–13.9) | 0.587 |
Platelet count (102/μL) | 163 (108–207) | 166 (116–207) | 157 (105–208) | 0.482 |
AST (U/L) | 36 (27–53) | 39 (26–56) | 35 (26–47) | 0.575 |
ALT (U/L) | 22 (18–36) | 22 (17–35) | 22 (18–41) | 0.861 |
LDH (U/L) | 213 (182–261) | 223 (190–290) | 196 (168–250) | 0.561 |
Albumin (g/dL) | 3.8 (3.5–4.1) | 3.8 (3.5–4.1) | 3.8 (3.5–4.1) | 0.573 |
Total bilirubin (mg/dL) | 0.7 (0.6–1.0) | 0.8 (0.6–1.0) | 0.7 (0.5–1.1) | 0.526 |
BUN (mg/dL) | 15.3 (13.4–20.0) | 15.3 (13.8–21.1) | 15.6 (12.8–18.6) | 0.244 |
Creatinine (mg/dL) | 0.81 (0.69–0.94) | 0.80 (0.70–0.99) | 0.82 (0.69–0.93) | 0.589 |
eGFR (mL/min/1.73 m2) | 68.2 (58.8–82.2) | 68.7 (56.3–85.2) | 68.1 (61.9–78.5) | 0.960 |
CKD | 18 (26.9) | 11 (33.3) | 7 (20.6) | 0.239 |
Total cholesterol (mg/dL) | 172 (156–206) | 170 (158–201) | 174 (154–208) | 0.957 |
Triglyceride (mg/dL) | 88 (62–122) | 88 (61–121) | 88 (62–131) | 0.796 |
High-Density Lipoprotein cholesterol (mg/dL) | 56 (46–72) | 53 (46–66) | 58 (48–73) | 0.423 |
Low-Density Lipoprotein cholesterol (mg/dL) | 102 (77–128) | 104 (78–130) | 95 (77–127) | 0.618 |
Blood glucose (mg/dL) | 99 (89–116) | 97 (88–102) | 101 (90–131) | 0.012 |
HbA1c (%) | 5.8 (5.5–6.6) | 5.7 (5.3–6.3) | 6.0 (5.7–6.7) | 0.034 |
